Aimmune Therapeutics Inc.
www.aimmune.com
Latest From Aimmune Therapeutics Inc.
US FDA's Shutdown Offers One Possible Winner
US FDA’s Biologics Center Faces Exciting 2019 After Quiet Year For Novel Approvals
Finance Watch: Recent Offerings Show Some Companies Were Ready For The Government Shutdown
Public Company Edition: The usual mid-January surge in public offerings hasn't happened this year, since the SEC can't process new filings, but Alnylam, Acceleron and others apparently were prepared for a lengthy shutdown. Also, ARM reports cell and gene therapy financing data.
Shutdown Bite Tightens At US FDA, But Gene Therapy To Get 50 More Reviewers
FDA continues to emphasize the routine and the positive, even though strains on staff and sponsors increase as shutdown grinds on. CBER's new clinical reviewers would oversee the clinical investigation, development and review of cell and gene therapies, although a timeline on the hiring is unclear.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Vaccines
- Therapeutic Areas
- Immune Disorders
- Alias(es)
- Allergen Research Corp.
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Aimmune Therapeutics Inc.
- Senior Management
-
Jayson Dallas, Pres. & CEO
Eric Bjerkholt, CFO
Jeffrey H Knapp, PhD, COO
Daniel C Adelman, MD, CMO
Mary Rozenman, PhD, SVP, Corp. Dev. & Strategy - Contact Info
-
Aimmune Therapeutics Inc.
Phone: (650) 614-5220
8000 Marina Blvd.
Ste. 300
Brisbane, CA 94005
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice